Literature DB >> 24619747

Evaluation of monoclonal and oligoclonal gammopathies in a pediatric population in a major urban center.

Matthew S Karafin1, Richard L Humphrey, Barbara Detrick.   

Abstract

OBJECTIVES: A growing body of literature has documented monoclonal proteins in children. Little is known about their associated diagnoses.
METHODS: We retrospectively evaluated all patients (aged 0-21 years) with abnormal findings on serum immunofixation electrophoresis (SIFE) from 2005 to 2011. We also documented the monoclonal immunoglobulin classes and light chain types involved and then correlated these data with the clinical diagnoses.
RESULTS: A total of 695 SIFE tests were performed on this patient population. Of these, 95 SIFE tests (14%) identified a gammopathy (from 83 different patients), and of these, 74 (11%) demonstrated only a monoclonal gammopathy (from 63 different patients). The most common associated diagnosis in the study interval was ataxia-telangiectasia (22%). No patient in the study population was diagnosed with multiple myeloma or Waldenström macroglobulinemia.
CONCLUSIONS: The significance and presence of a monoclonal or oligoclonal gammopathy in pediatric and young adult populations is distinct from that seen in adults.

Entities:  

Keywords:  Gammopathy; Monoclonal; Oligoclonal; Pediatric

Mesh:

Year:  2014        PMID: 24619747     DOI: 10.1309/AJCP2JBDEELPA7HT

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

1.  Monoclonal Gammopathy of Unclear Significance in a Child with Wiskott-Aldrich Syndrome: a Rare Occurrence.

Authors:  Rashmi Rikhi; Sagar Bhattad; Ankur Jindal; Biman Saikia; Ravinder Garg; Amit Rawat; Deepti Suri; Surjit Singh
Journal:  J Clin Immunol       Date:  2019-01-03       Impact factor: 8.317

2.  The light at the end of the tunnel: an unusual case of acute kidney injury in a pediatric patient: Answers.

Authors:  Miriam Steinberg; Joseph P Gaut; Stanley Paul Hmiel; Aadil Kakajiwala
Journal:  Pediatr Nephrol       Date:  2018-03-09       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.